ORAGENICS INC (OGEN)
$0.52-$0.01 (-1.47%) Today
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 55,900 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
7 Form 4 filings on record, the earliest from Dec 9, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John Spencer - Officer | Grant or award | Employee Stock Option (right to buy) | 55,900 | $0.00 | - | |
| Fred Telling - Director | Open-market sale | Common Stock | 210 | $0.94 | $198 | |
| Fred Telling - Director | Grant or award | Non-Employee Director Option (Right to Buy) | 125,000 | $0.00 | - | |
| Odyssey Health, Inc. - 10% Owner | Open-market sale | Common Stock - OGEN | 2,000 | $4.46 | $9K | |
| Odyssey Health, Inc. - 10% Owner | Open-market sale | Common Stock - OGEN | 5,044 | $4.26 | $21K | |
| Odyssey Health, Inc. - 10% Owner | Open-market sale | Common Stock - OGEN | 5,000 | $4.27 | $21K | |
| Odyssey Health, Inc. - 10% Owner | Open-market sale | Common Stock - OGEN | 5,000 | $4.45 | $22K | |
| Robert C. Koski - Director | Other | Common Stock | 5,000 | - | - | |
| Robert C. Koski - Director | Other | Series B Convertible Preferred Stock | 1,500,000 | - | - | |
| Alan W. Dunton - Director | Open-market sale | Common Stock | 66 | $10.80 | $24 | |
| Fred Telling - Director | Open-market sale | Common Stock | 3,597 | $10.80 | $1K |
ORAGENICS INC (OGEN) had 1 insider filing in the last 90 days, with the most recent on 2026-07-07. The full record for OGEN runs to 7 Form 4 filings, the earliest from 2024-12-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of OGEN were filed in the last 90 days.
No insider sales of OGEN were filed in the last 90 days. 7 sales are on record for this company.
This page tracks OGEN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add OGEN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
